SynthesisCancer immunology, immunotherapy : CII2025

Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review.

Toshali Pandey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.